复发难治性恶性脑膜瘤3例抗血管生成治疗临床分析

摘要

目的 探讨复发难治性恶性脑膜瘤的抗血管生成治疗疗效.方法 回顾性分析复发难治性恶性脑膜瘤使用抗血管生成药物贝伐珠单抗治疗的3例病例临床资料.结果 3例患者使用贝伐珠单抗后MRI均可见到T2 FLAIR相水肿范围缩小,2例患者增强病灶稳定,1例患者缩小.3例患者临床症状均有缓解,无疾病进展时间分别为2.5、5、7个月.结论 贝伐珠单抗使用于常规治疗后复发难治性的恶性脑膜瘤大部分患者可获得临床症状缓解,影像上肿瘤控制,但控制时间有限,难达到临床治愈.%Objective To investigate the effect of anti -angiogenesis therapy for refractory malignant meningio-ma.Methods The clinical data of 3 cases of refractory malignant meningioma treated with anti -angiogenic drug Bev-acizumab (avastin) were retrospectively analyzed .Results Post treatment, the volume of edema was decreased in MR T2 FLAIR images.Two patients had stable enhanced lesion and one patient had increased enhanced lesion .The clinical symptoms of 3 patients were improved , and the progression-free time were 2.5, 5 and 7 months respectively .Conclu-sion Patients with refractory malignant meningioma could slightly benefit from the aid of Bevacizumab post conventional treatment.It is still difficult to cure refractory malignant meningiomas .